Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-J591 in metastatic androgen-independent prostate cancer
NCT00195039Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Aug 2004
- Primary completion
- Feb 2012
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of 177lu-rosopatamab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Weill Cornell Medicine. Started Aug 2004; status: completed.
02
Drugs
177lu-rosopatamab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00195039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00195039.